Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

Why an HIV patient advocacy group is suing the Trump administration over a Biden administration legal settlement with Gilead ...

Analysts lift targets for Gilead as HIV sales surge and Yeztugo launch gains traction, supporting a stronger full-year ...

Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...

The U.S. Preventive Services Task Force makes recommendations for preventive services—including Gilead’s twice-yearly HIV ...

The FDA's top regulator of cancer drugs interceded in a review of a Replimune skin cancer therapy, contributing to its ...

Washington has long failed to come up with a solution for rising drug prices that addresses the concerns of drugmakers, ...

Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, exceeding prior estimates.

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...